Nephros, Inc. (NASDAQ:NEPH – Get Free Report) was the recipient of a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 8,300 shares, a decline of 13.5% from the February 13th total of 9,600 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily volume of 13,400 shares, the short-interest ratio is currently 0.6 days.
Nephros Stock Performance
Shares of NASDAQ:NEPH traded down $0.02 during trading on Wednesday, reaching $1.50. The stock had a trading volume of 7,933 shares, compared to its average volume of 12,819. Nephros has a 52 week low of $1.36 and a 52 week high of $2.55. The firm’s fifty day moving average is $1.56 and its 200 day moving average is $1.58. The stock has a market cap of $15.82 million, a price-to-earnings ratio of -16.67 and a beta of 1.19.
Institutional Trading of Nephros
An institutional investor recently bought a new position in Nephros stock. Topline Capital Management LLC bought a new position in Nephros, Inc. (NASDAQ:NEPH – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 419,887 shares of the company’s stock, valued at approximately $617,000. Topline Capital Management LLC owned approximately 3.98% of Nephros as of its most recent filing with the Securities and Exchange Commission (SEC). 41.10% of the stock is owned by institutional investors and hedge funds.
Nephros Company Profile
Nephros, Inc, a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.
Featured Stories
- Five stocks we like better than Nephros
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Alphabet’s Officially In A Bear Market—Time To Buy?
- What Are Dividend Achievers? An Introduction
- D-Wave and Quantum Supremacy: Implications For Investors
- What is MarketRank™? How to Use it
- 3 Cash Cow Stocks Leading Their Sectors in Free Cash Flow Margins
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.
